Effect of Age on Leukopenia Following Renal Transplantation at a Single Center.
| Autor: | Yang Y; Department of Pharmacy, SUNY Downstate Medical Center, Brooklyn, NY, USA., Guerra CM; Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA.; Department of Surgery, Transplant Center, University of Texas Health Science Center, San Antonio, TX, USA., Sumrani N; Department of Transplant, SUNY Downstate Medical Center, Brooklyn, NY, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Progress in transplantation (Aliso Viejo, Calif.) [Prog Transplant] 2019 Mar; Vol. 29 (1), pp. 54-60. Date of Electronic Publication: 2018 Dec 04. |
| DOI: | 10.1177/1526924818817017 |
| Abstrakt: | Introduction: Leukopenia in renal transplant recipients occurs commonly within the first year following transplantation; however, literature on the effects of age on leukopenia is scarce. Design: A single-center, retrospective review was conducted on 141 recipients transplanted from January 2011 to December 2015. Transplant recipients were characterized by age <60 years (n = 94) or age 60 years and older (n = 47) for analysis. Results: A greater incidence of leukopenia was seen in the older cohort compared to the younger cohort (64% vs 55%). Of those patients who developed leukopenia, the older cohort (n = 30) had a higher incidence of hospitalization for leukopenia (30% vs 23%) but a lower incidence of hospitalization for infection (20% vs 25%) compared to the younger cohort (n = 52). Additionally, one month following mycophenolate mofetil (MMF) discontinuation, the older cohort had reduced recovery of their white blood cell count (+263.8% vs +272.5%) and experienced less recurrent leukopenic episodes (50% vs 67%) and rejection episodes (0% vs 22%) compared to the younger cohort, alluding to the need for less immunosuppression. Conclusions: Age at transplantation was not associated with the development of leukopenia; however, older patients had a higher incidence of leukopenia and hospitalization for leukopenia. Dose reduction or discontinuation of MMF should be considered in older kidney transplant recipients who develop leukopenia. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|